Mark Sheptoff Financial Planning, LLC Travere Therapeutics, Inc. Transaction History
Mark Sheptoff Financial Planning, LLC
- $177 Million
- Q1 2025
A detailed history of Mark Sheptoff Financial Planning, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Mark Sheptoff Financial Planning, LLC holds 2,400 shares of TVTX stock, worth $51,384. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,400Holding current value
$51,384% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
224Shares Held
94.1MCall Options Held
1.62MPut Options Held
774K-
Black Rock Inc. New York, NY7.64MShares$164 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$158 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$107 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$106 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$91.2 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.37B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...